cabozantinib
FDA Approves Cabometyx for pNET and epNET
The FDA granted approval for Cabometyx for adult and pediatric patients 12 years of age and older with previously ...
MARCH 26, 2025
Cabometyx Approved for Metastatic Differentiated Thyroid Cancer
The FDA approved cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age and older with ...
SEPTEMBER 30, 2021
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 16, 2019
Cabometyx Approved for First-Line Treatment of Advanced RCC
The FDA has granted regular approval to cabozantinib (Cabometyx, Exelixis) for the treatment of patients with ...
DECEMBER 20, 2017
Load more